SOT102 News - LARVOL Sigma

||||||||||  SOT102 / Sotio, Boehringer Ingelheim
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  CLAUDIO-01: Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (clinicaltrials.gov) -  May 28, 2024
P1/2, N=160, Recruiting,  Sponsor: SOTIO Biotech a.s.
Suspended --> Recruiting | N=269 --> 160 | Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Dec 2023 --> Dec 2027

||||||||||  SOT102 / Sotio, Boehringer Ingelheim
Trial suspension, Combination therapy, Monotherapy, Metastases:  CLAUDIO-01: Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Nov 27, 2023
P1/2, N=269, Suspended,  Sponsor: Sotio Biotech Inc.
Suspended --> Recruiting | N=269 --> 160 | Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Dec 2023 --> Dec 2027 Recruiting --> Suspended

|||||||||| SOT102 / Sotio, Boehringer Ingelheim
SOT102, A Novel CLDN18.2- Targeting Antibody-Drug Conjugate for Gastric & Pancreatic Cancer with Wide Range of Target Expression () - Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_121;
Recruiting --> Suspended Outlining the engineering of a Claudin18.2 targeting antibody; Outlining the preclinical development of SOT102, a novel PNU-based antibody

|||||||||| SOT102 / Sotio, Boehringer Ingelheim
CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2295;
P1/2
Outlining the engineering of a Claudin18.2 targeting antibody; Outlining the preclinical development of SOT102, a novel PNU-based antibody The trial consists of the following modules:

|||||||||| SOT102 / Sotio, Boehringer Ingelheim
SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression (Hall Bordeaux) - Jan 31, 2023 - Abstract #ESMOTAT2023ESMO_TAT_125;
P1/2
Conclusions SOT102 represents a novel potent ADC with the potential to treat Claudin 18.2 expressing tumors irrespective of the intensity of expression. The first in human dose escalation trial has been initiated in patients with gastric and pancreatic cancer.

|||||||||| SOT102 / Sotio, Boehringer Ingelheim
Introducing SOT102, a Claudin 18.2 Targeting PNU-based ADC into Clinical Development () - Jul 8, 2022 - Abstract #ADCUSA2022ADC_USA_91;
The first in human dose escalation trial has been initiated in patients with gastric and pancreatic cancer. Outlining the design of ongoing first-in-human trials Sharing preliminary interim data of first-inhuman trials Overviewing the next step into broader clinical development

|||||||||| SOT102 / Sotio, NBE Therap
[VIRTUAL] SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels () - Mar 11, 2021 - Abstract #AACR2021AACR_788;
Stability of SO-N102 without any significant loss of the payload was demonstrated in vitro and in animals. Further toxicology studies in rats and cynomolgus monkeys were initiated, paralleled by process development and manufacturing activities with the plan to initiate the first clinical study with SO-N102 in patients in the first half of 2022.



	Diseases Companies Products Productz Mechanisms of Action Sites